AVITA Medical, Inc. (RCEL) Revenue (2018 - 2026)

AVITA Medical (RCEL) has reported Revenue for 9 consecutive years, with $21.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 17.83% year-over-year to $21.7 million; the trailing twelve-month figure through Jun 2026 stood at $149.2 million (up 99.22% YoY), and the FY2025 full-year result was $71.6 million, up 11.45% from the prior year.
• Revenue retreated to $21.7 million in Q2 2026 per RCEL's latest filing, from $92.0 million in the prior quarter.
• Across five years, Revenue topped out at $92.0 million in Q4 2025 and bottomed at $7.5 million in Q1 2022.
• Historically, Revenue has averaged $19.3 million across 5 years, with a median of $14.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue slumped 65.15% in 2022, then soared 399.84% in 2025.
• Over 5 years, Revenue stood at $9.5 million in 2022, then jumped by 50.13% to $14.2 million in 2023, then increased by 29.67% to $18.4 million in 2024, then jumped by 399.84% to $92.0 million in 2025, then plunged by 76.41% to $21.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $21.7 million, $92.0 million, and $17.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.